Bioheart Partners (BHRT) With Life Technologies (LIFE) to Offer Myoblast Cell Products to the Research Market
More News related to BHRT
- Bioheart Elects Lee Jones to Its Board of Directors
- Bioheart Partners (BHRT) With Life Technologies (LIFE) to Offer Myoblast Cell Products to the Research Market
- Bioheart (BHRT) Announces CE Marking for TGI 1200(tm) Adult Stem Cell Isolation System
- Bioheart (BHRT) Board Appoints Howard J. Leonhardt CEO
- Bioheart (BHRT) Reports a Q1 Loss
More News related to LIFE
- InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
- Beacon Equity Issues Technical Trading Overview for Questcor Pharmaceuticals Inc.
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Life Technologies Addresses Promise of Cell Therapies at Industry Leader Summit
- Trading Outlook for StemCells Inc. Issued by InvestorSoup.com
More News related to Corporate News
- Magal Security Systems (MAGS) Posts Q3 Loss of $0.07, Narrower Y/Y
- Telvent (TLVT) Posts Q3 Non-GAAP EPS of €0.32, Better Y/Y; Revs Higher
- Inergy Holdings (NRGP) Posts Q4 Loss of $0.79, Below Estimates; Guides
- Patriot Transportation (PATR) Posts Q4 EPS of $0.32, MIsses Estimates
- Unify Corporation (UNFY) Posts Q2 non-GAAP EPS of $0.02, Down Y/Y; Revs Higher; Guides
Bioheart, Inc. (Nasdaq: BHRT) and Life Technologies Corporation (Nasdaq: LIFE) have entered into a global distribution and OEM agreement to sell myoblast cell-based research products to life science researchers. Life Technologies will offer Bioheart's myoblast stem cell products to the research community so that they may accelerate the development of myoblast stem cell applications.
Myoblasts, or muscle derived stem cells, have been utilized in more than 7,000 scientific papers and abstracts in a variety of indications from heart failure to muscular dystrophy. In particular, when injected into scar tissue within the heart wall, myoblasts have been shown to be capable of engrafting in the damaged tissue and differentiating into mature skeletal muscle cells. Myoblasts are the only cell which has demonstrated an ability to generate new muscle tissue within the scarred regions of a heart.
Bioheart is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
